Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierluigi Russo

Showing results (41-50 of 133) with videos related to

Pageof 14
Sort By:
Journal of Immunoassay & Immunochemistry|January 2, 2009
Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centresFrancesca Bellomi, Placido Bramanti, Maria Trojano, et al.
Journal of Clinical Medicine|May 13, 2026
Lifestyle Interventions in Patients in Active Surveillance for Prostate Cancer: A Systematic ReviewMarco Campetella, Francesco Pio Bizzarri, Pierluigi Russo, et al.
Annals of Hematology|March 14, 2023
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)Massimo Breccia, Pier Paolo Olimpieri, Simone Celant, et al.
European Heart Journal|June 27, 2015
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB DatabaseGian Paolo Fadini, Angelo Avogaro, Luca Degli Esposti, et al.
International Journal of Cancer|October 5, 2022
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registryBruno Vincenzi, Andrea Napolitano, Alessandro Comandone, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 8, 2006
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosisMaria Trojano, Pierluigi Russo, Aurora Fuiani, et al.
Minerva Urology and Nephrology|January 20, 2025
Cytology's sunset: is it time to embrace new biomarkers for upper tract urothelial carcinoma?Savio D Pandolfo, Fabio Crocerossa, Celeste Manfredi, et al.
Urologia|November 8, 2024
Efficacy of the Rezūm System for lower urinary tract symptoms in patients with benign prostatic hyperplasia: Long term results from a single centre prospective studyAngelo Totaro, Filippo Gavi, Daniele Fettucciari, et al.
Cancers|March 28, 2026
Nerve-Sparing in High-Risk Prostate Cancer: Advantages and Pitfalls of Current Strategies and TechnologiesDaniele Robesti, Pierluigi Russo, Giuseppe Fallara, et al.
Journal of Clinical Medicine|June 13, 2025
Prostate Artery Embolization (PAE) in the Treatment of Benign Prostatic Hyperplasia: A Case Series and Narrative ReviewVincenzo Iossa, Ernesto Punzi, Savio Domenico Pandolfo, et al.
Pageof 14

Showing results (41-50 of 133) with videos related to

Sort By:
Pageof 14
Journal of Immunoassay & Immunochemistry|January 2, 2009
Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centresFrancesca Bellomi, Placido Bramanti, Maria Trojano, et al.
Journal of Clinical Medicine|May 13, 2026
Lifestyle Interventions in Patients in Active Surveillance for Prostate Cancer: A Systematic ReviewMarco Campetella, Francesco Pio Bizzarri, Pierluigi Russo, et al.
Annals of Hematology|March 14, 2023
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)Massimo Breccia, Pier Paolo Olimpieri, Simone Celant, et al.
European Heart Journal|June 27, 2015
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB DatabaseGian Paolo Fadini, Angelo Avogaro, Luca Degli Esposti, et al.
International Journal of Cancer|October 5, 2022
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registryBruno Vincenzi, Andrea Napolitano, Alessandro Comandone, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 8, 2006
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosisMaria Trojano, Pierluigi Russo, Aurora Fuiani, et al.
Minerva Urology and Nephrology|January 20, 2025
Cytology's sunset: is it time to embrace new biomarkers for upper tract urothelial carcinoma?Savio D Pandolfo, Fabio Crocerossa, Celeste Manfredi, et al.
Urologia|November 8, 2024
Efficacy of the Rezūm System for lower urinary tract symptoms in patients with benign prostatic hyperplasia: Long term results from a single centre prospective studyAngelo Totaro, Filippo Gavi, Daniele Fettucciari, et al.
Cancers|March 28, 2026
Nerve-Sparing in High-Risk Prostate Cancer: Advantages and Pitfalls of Current Strategies and TechnologiesDaniele Robesti, Pierluigi Russo, Giuseppe Fallara, et al.
Journal of Clinical Medicine|June 13, 2025
Prostate Artery Embolization (PAE) in the Treatment of Benign Prostatic Hyperplasia: A Case Series and Narrative ReviewVincenzo Iossa, Ernesto Punzi, Savio Domenico Pandolfo, et al.
Pageof 14